Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
暂无分享,去创建一个
R. Giugliano | E. Braunwald | C. Cannon | S. Murphy | E. Bohula | M. Blazing | A. Tershakovec | Jennifer A. White | Jing Zhou
[1] R. Giugliano,et al. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? , 2015, Journal of the American College of Cardiology.
[2] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[3] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[4] W. Weintraub,et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.
[5] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[6] J. Danesh,et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data , 2011, BMJ : British Medical Journal.
[7] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[8] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[9] Shahrul Mt-Isa,et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.
[10] J. Liao,et al. Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.
[11] D. Gómez-Garre,et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid‐lowering effect , 2009, British journal of pharmacology.
[12] C. Ballantyne,et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. , 2009, The American journal of cardiology.
[13] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[14] R. Califf,et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.
[15] C. Ballantyne,et al. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. , 2007, The American journal of cardiology.
[16] M. Pfeffer,et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[17] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[18] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[19] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[20] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[21] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[22] C. Ballantyne,et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. , 2004, The American journal of cardiology.
[23] Robert Kleemann,et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. , 2004, Blood.
[24] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[25] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[26] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[27] Meehyung Cho,et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.
[28] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.
[29] Kathleen M. Weil,et al. Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction , 2002, Circulation.
[30] R. Collins,et al. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[31] D. Cutler,et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. , 2000, British journal of clinical pharmacology.
[32] A. Coats. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[33] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[34] S. Basili,et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.
[35] M. Pfeffer,et al. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .
[36] M. Pfeffer,et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.
[37] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[38] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[39] C. Visser,et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.
[40] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[41] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.